Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

NCT06238167 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Tislelizumab
DRUG: S-1 therapy
DRUG: low dose SOX therapy

Sponsor

First Affiliated Hospital of Wenzhou Medical University